Source: Virtual Congress 2021 – COVID - 19 treatments



Rating:

Share or cite this content

Citations should be made in the following way:
S. Zubair (karachi, Pakistan), A. Zahid (karachi, Pakistan), T. Shahzad (karachi, Pakistan), A. Zubairi (karachi, Pakistan), J. Ahmed Khan (karachi, Pakistan), M. Irfan (karachi, Pakistan). Role of ivermectin in hospitalized patients with mild to moderate COVID-19.. 3666

Member's Comments

No comment yet.

Related content which might interest you: Effects of exercise in patients with moderate to severe asthma Source: Annual Congress 2008 - Risk factors for asthma versus asthma control Year: 2008 Role of exercise rehabilitation in mild & moderate COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 214s Year: 2004 Impact of moderate and severe exacerbations in severe COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018 Comparison of the effect of short course of oral prednisone in patients with moderate and severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 281s Year: 2003 Residual symptoms in moderate to severe COVID-19 patients Source: Virtual Congress 2021 – COVID - 19 Year: 2021 Evaluation of pain pressure threshold in patients with moderate to severe symptomatic COPD and healthy controls Source: Virtual Congress 2020 – Prognosis and integrated management of COPD Year: 2020 Effect of erdosteine in moderately severe COPD patients Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Efficacy of ruzam in the treatment of patients with mild-to-moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 The effect of long-term treatment with erdosteine on moderate or severe COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005 Long-term efficacy of 1 year anti-inflammatory treatment in paediatric patients with mild persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004 Prevalence of psychiatric disorders in 143 consecutive moderate to severe COPD patients in a pulmonary outpatient facility in Germany Source: Eur Respir J 2006; 28: Suppl. 50, 160s Year: 2006 Patterns of resolution of acute severe asthma in children when treated with oral prednisolone Source: Eur Respir J 2001; 18: Suppl. 33, 122s Year: 2001 Prevalence and impact of comorbidities in Tunisian moderate to severe COVID-19 patients Source: Virtual Congress 2021 – COVID - 19 around the globe Year: 2021 Comparison of the efficacy of cicleosonide with budesonide in mild to moderate asthma patients after step-down therapy Source: Annual Congress 2011 - Asthma management and response Year: 2011 Effect of ABPA treatment in severe asthma patients with acute and relapsed disease Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Home-based evaluation in patients with high risk for moderate to severe OSA Source: Annual Congress 2012 - CPAP: beneficial effects on different aspects of health Year: 2012 Characterization of patients with severe COPD Source: International Congress 2018 – COPD around the world Year: 2018 Prevalence of distal airways impairment in a survey of moderate to severe asthmatic patients with normal FEV1 Source: Annual Congress 2010 - Prevalence and incidence of asthma and COPD Year: 2010 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020